Lv3
340 积分 2023-02-05 加入
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
10小时前
已完结
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
10小时前
已完结
Therapeutic landscape and future direction of metastatic colorectal cancer
7天前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
16天前
已完结
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
21天前
已完结
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
21天前
已完结
OA03.04 A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
21天前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
21天前
已完结
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
1个月前
已完结
Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors
1个月前
已完结
皖公网安备34019202002308
